Recent research in the treatment of multiple sclerosis (MS) has yielded new therapies. Specifically, copolymer-1, a mixture of synthetic polypeptides composed of four amino acids has been effective in reducing relapse rates and disability in patients with relapsing-remitting MS. In a two-year multicenter, randomized, double-blind, placebo-controlled trial of 251 patients, copolymer-1 was shown ...

Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator and the first oral therapy for relapsing-remitting multiple sclerosis. Its use has been complicated by a low rate of cystoid macular edema usually in the first 3 months after commencement of the medication. We report the case of a 34-year-old male with relapsing-remitting multiple sclerosis, who developed acute anterior uvei...

objective: micrornas (mirna) are a class of non-coding rnas which play key roles in post-transcriptional gene regulation. previous studies indicate that mirnas are dysregulated in patients with multiple sclerosis (ms). th17 and regulatory t (treg) cells are two subsets of cd4+ t-cells which have critical functions in the onset and progression of ms. the current study seeks to distinguish fluctu...

Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 FTA recommend diroximel fumarate (Vumerity) the management of relapsing remitting multiple sclerosis (RRMS). short article explores pote...

In the past 10 years, the treatment options for patients with relapsing-remitting multiple sclerosis (RRMS) underwent some major changes. After relying on injectable interferon-beta preparations for quite some time, the advent of the first monoclonal antibody, natalizumab, followed by the first oral drug, fingolimod, improved the outcome of these patients and the possibilities to treat them mor...